Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ: EXAS) said the Hart-Scott-Rodino waiting period expired for its exclusive U.S. license to Freenome’s blood-based colorectal cancer screening tests.

The license grants exclusive U.S. rights but remains conditional on Freenome’s test receiving first-line FDA approval. Exact Sciences updated 2025 guidance to reflect an initial $75 million cash payment, lowering full-year adjusted EBITDA guidance to $395–$405 million from $470–$480 million while leaving revenue guidance unchanged at $3.220–$3.235 billion.

Exact Sciences (NASDAQ: EXAS) announced pivotal ALTUS study results showing its Oncoguard Liver blood test outperformed ultrasound for hepatocellular carcinoma (HCC) surveillance in a prospective U.S. trial of >3,000 participants. The test met the primary endpoint, detecting early-stage HCC by Milan criteria 67% vs 22% for ultrasound, with very early-stage sensitivity 64% vs 9% and early-stage sensitivity 77% vs 36%. Oncoguard Liver specificity was 82%. Results will be presented as late-breaking data at AASLD The Liver Meeting on November 11, 2025 and are planned for peer-reviewed publication. The assay combines DNA methylation and protein markers and was developed with Mayo Clinic.

Exact Sciences (Nasdaq: EXAS) said company management will participate in the Jefferies London Healthcare Conference in London and invited investors to join a webcast of the fireside chat.

The event is scheduled for Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT). The webcast is available in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

Exact Sciences (NASDAQ: EXAS) presented new real-world and modeling data at ACG 2025 showing the Cologuard mt-sDNA test and care-gap programs can raise colorectal cancer (CRC) screening and detection versus FIT.

Key findings: prior mt-sDNA users completed screening at 53.4% in a Medicare Advantage care-gap program vs 38.8% for other stool-test users; digital outreach raised completion odds by 129%. A cost-model (1M cohort) showed next-generation mt-sDNA screened 713,000 vs 318,000 for FIT, detected more advanced lesions (21,701 vs 3,328) and CRC cases (2,090 vs 440), and reduced total modeled costs ($1,388M vs $1,423M).

Exact Sciences (NASDAQ: EXAS) will release its third quarter 2025 financial results after market close on November 3, 2025. Company management will host a webcast and conference call at 5:00 p.m. ET the same day to discuss results and business progress. The live webcast and a replay will be available at www.exactsciences.com. Telephone access is available for domestic and international callers using access code 4437608.

Investors and other interested parties can join the live webcast or listen by phone; a replay will be posted on the company website.

Exact Sciences (NASDAQ: EXAS) announced a modeling study published in JNCI showing Cologuard Plus, a triennial next‑generation mt‑sDNA test, was the only noninvasive option classified as efficient for screening ages 45–75, delivering the most life‑years gained with the fewest colonoscopies.

The study used the validated CRC‑AIM microsimulation and CISNET methodology, incorporated new clinical data, and reported Cologuard Plus sensitivity of 95% for CRC and specificity of 94% in U.S. screening‑age adults.

Findings note annual FIT was near‑efficient; mt‑RNA and blood‑based tests were not efficient at recommended intervals.

Exact Sciences (NASDAQ: EXAS) has partnered with horror film actor Matthew Lillard to promote colorectal cancer screening through their Cologuard® test. The SCREEN campaign aims to reduce fear around colon cancer screening, highlighting Cologuard as a noninvasive, at-home testing option for those 45 and older.

The campaign emphasizes that Cologuard has been used over 20 million times since FDA approval in 2014. When detected early, colon cancer has a 90% survival rate. The test requires no special preparation and can be completed at home, making it a convenient screening option for individuals at average risk of colorectal cancer.

Exact Sciences (NASDAQ: EXAS) has launched Cancerguard™, a groundbreaking multi-cancer early detection (MCED) blood test priced at $689. The test is the first to analyze multiple biomarker classes and can detect over 50 cancer types, including those responsible for 80% of annual U.S. cancer diagnoses.

Key performance metrics include 68% sensitivity across six deadliest cancers, 64% overall sensitivity across broader cancer types, and 97.4% specificity. The test can detect more than a third of Stage I or II cancers. Modeling suggests that over 10 years, using Cancerguard alongside current screening methods could reduce Stage IV diagnoses by 42% and lower cancer mortality by 18%.

Nationwide accessibility will be facilitated through Quest Diagnostics' 7,000 patient access sites, with broader consumer telehealth access starting October 2025.